<SEC-DOCUMENT>0001193125-18-287773.txt : 20180928
<SEC-HEADER>0001193125-18-287773.hdr.sgml : 20180928
<ACCEPTANCE-DATETIME>20180928172706
ACCESSION NUMBER:		0001193125-18-287773
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180928
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180928
DATE AS OF CHANGE:		20180928

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACHIEVE LIFE SCIENCES, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		181095082

	BUSINESS ADDRESS:	
		STREET 1:		520 PIKE STREET
		STREET 2:		SUITE 2250
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		425-686-1500

	MAIL ADDRESS:	
		STREET 1:		520 PIKE STREET
		STREET 2:		SUITE 2250
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ONCOGENEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d584378d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): September&nbsp;28, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ACHIEVE LIFE SCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">033-80623</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">95-4343413</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1001 W. Broadway, Suite&nbsp;400</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vancouver, BC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>V6H 4B1</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s Telephone Number, Including Area Code: (604)
<FONT STYLE="white-space:nowrap">736-3678</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;27, 2018, Achieve Life Sciences, Inc. (the &#147;Company&#148;) announced results of a clinical study demonstrating similar bioavailability
for a new cytisine formulation in fed and fasted subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;18, 2018, the Company announced that the International Journal of Drug
Policy published data demonstrating superior cytisine abstinence rates compared to nicotine replacement therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of the related press releases are
filed as Exhibits 99.1 and 99.2 hereto and are incorporated by reference herein.<B> </B> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d584378dex991.htm">Press release of Achieve Life Sciences, Inc. dated September&nbsp;27, 2018 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d584378dex992.htm">Press release of Achieve Life Sciences, Inc. dated September&nbsp;18, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ACHIEVE LIFE SCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: September&nbsp;28, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Bencich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">John Bencich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d584378dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g584378g13v56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed
and Fasted Subjects </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SEATTLE, Wash and VANCOUVER, British Columbia, Sept. 27, 2018</B> &#151; Achieve Life Sciences, Inc. (NASDAQ: ACHV), a
clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of a new formulation
for cytisine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study evaluated the bioavailability of a new formulation of 3 mg cytisine under fed and fasted conditions in 12 healthy volunteer
smokers. Study results demonstrated bioequivalence when cytisine was administered with or without food.&nbsp;Cytisine was extensively absorbed after oral administration with maximum cytisine concentration levels observed in the blood within less
than two hours with or without food. Total excretion levels of cytisine also remained equivalent in both the fed and fasted states, and the 3 mg dose of this new formulation of cytisine was very well tolerated. These results are similar to results
evaluating the previous cytisine formulation for bioavailability under fed and fasted conditions in 24 healthy, <FONT STYLE="white-space:nowrap">non-smoking</FONT> volunteers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We believe this new cytisine formulation will allow for an extended shelf-life and will be used in the upcoming Phase 2b clinical trial as well as the
Phase 3 clinical program,&#148; said Rick Stewart, Chairman and CEO of Achieve. &#147;We are pleased with the similar results regarding this new formulation in smokers and that the higher dose of 3 mg cytisine continues to demonstrate a good safety
profile with or without food.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytisine is an established smoking cessation treatment that has been approved and marketed in Central and Eastern
Europe for more than 20 years. It is estimated that over 20&nbsp;million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase 3 clinical trials in Europe and New Zealand. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cytisine </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Achieve&#146;s focus is to address the
global smoking health epidemic through the development and commercialization of cytisine. Tobacco use is currently the leading cause of preventable death and is </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsible for nearly six million deaths annually worldwide<SUP STYLE="font-size:85%; vertical-align:top">[1]</SUP>. It is estimated that 28.6% of all cancer deaths in the U.S. are attributable
to cigarette smoking<SUP STYLE="font-size:85%; vertical-align:top">[2]</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytisine is a plant-based alkaloid with a high binding affinity to the
nicotinic acetylcholine receptor. Two prior, large-scale Phase 3 clinical studies of cytisine, with favorable outcomes, have been successfully completed in over 2,000 patients. The TASC trial was a 740 patient, double-blind, placebo controlled trial
conceived by Professor Robert West at University College London and funded by the U.K. National Prevention Research Initiative. The CASCAID trial was a 1,310 patient, single-blind, <FONT STYLE="white-space:nowrap">non-inferiority</FONT> trial
comparing cytisine to nicotine replacement therapy (NRT). The CASCAID trial was conceived by Dr.&nbsp;Natalie Walker, National Institute for Health Innovation, University of Auckland and funded by the Health Research Council of New Zealand. Both
trials were published in the New England Journal of Medicine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform
Act of 1995, including, but not limited to, statements regarding the planned cytisine clinical development activities, the potential market size for cytisine and the potential benefits of cytisine. All statements other than statements of historical
fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections
disclosed in these forward-looking statements. These statements are based on management&#146;s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially
from those described in the forward-looking statements, including, among others, the risk that cytisine may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the
development of cytisine; the risk that cytisine will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development
plans; the risk that Achieve&#146;s intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve&#146;s filings with the Securities and
Exchange Commission from time to time, including Achieve&#146;s Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Achieve undertakes no obligation to
update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Achieve Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason Wong </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jwong@bplifescience.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(415)
<FONT STYLE="white-space:nowrap">375-3340</FONT> ext. 4 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">[1]</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">World Health Organization. WHO Report on the Global Tobacco Epidemic, 2011, Geneva: World Health Organization,
2011. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">[2]</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annals of Epidemiology , Volume 25 , Issue 3 , 179 &#150; 182.e1 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d584378dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g584378g13v56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Achieve Announces Positive Cytisine Data Published in International Journal of Drug Policy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cytisine Demonstrated Superior Abstinence Rates Compared to Nicotine Replacement Therapy </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SEATTLE, Wash. and VANCOUVER, British Columbia, Sept. 18, 2018</B> &#151; Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical
company committed to the global development and commercialization of cytisine for smoking cessation, today announced the publication of new cytisine data from an independent observational study in the International Journal of Drug Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The observational study compared the effectiveness of cytisine and nicotine replacement therapy (NRT) as an aid to smoking cessation in the Russian
Federation. Evaluation of 301 subjects who had used either cytisine or NRT determined that smokers in the cytisine group were approximately three times more likely to achieve <FONT STYLE="white-space:nowrap">90-days</FONT> abstinence compared to
those who attempted to quit with NRT (p=0.011). As demonstrated in prior cytisine studies, the highest abstinence rates were observed in subjects who also received smoking cessation behavioral support and counseling. Cytisine was found to be well
tolerated. The authors concluded the findings support previous trial evidence indicating that cytisine is superior to NRT for achieving short- and long-term abstinence and should be considered a first-line pharmacologic treatment for smoking
cessation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rick Stewart, Chairman and Chief Executive Officer of Achieve Life Sciences commented, &#147;These data provide further real-world evidence on
the important role cytisine can play in helping smokers quit. Cytisine has been commercially available in numerous countries in Central and Eastern Europe for decades and our mission is to make it a globally available treatment option for people
battling nicotine addiction.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full article <I>&#147;The effectiveness of Cytisine versus Nicotine Replacement Treatment for Smoking cessation in
the Russian Federation&#148;</I> can be accessed by visiting <FONT STYLE="white-space:nowrap">https://www.ijdp.org/article/S0955-3959(18)30161-0/fulltext.</FONT> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Study </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Study data were obtained from the 2009 Russian Global Adult Tobacco Survey of more than 11,000 individuals. The observational study utilized cross-sectional
data to compare self-reported <FONT STYLE="white-space:nowrap">30-day</FONT> and <FONT STYLE="white-space:nowrap">90-day</FONT> smoking abstinence rates of smokers who used either cytisine or NRT as an aid to smoking cessation. This analysis
evaluated 301 subjects, including 88 in the cytisine arm and 186 in the NRT arm. Subjects who utilized combination methods or pharmacotherapy in the prior year were not included in the analysis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Achieve&nbsp;&amp; Cytisine </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Achieve&#146;s focus
is to address the global smoking health epidemic through the development and commercialization of cytisine. Tobacco use is currently the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide<SUP
STYLE="font-size:85%; vertical-align:top">[1]</SUP>. It is estimated that 28.6% of all cancer deaths in the U.S. are attributable to cigarette smoking<SUP STYLE="font-size:85%; vertical-align:top">[2]</SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Two prior, large-scale Phase 3 clinical studies of
cytisine, with favorable outcomes, have been successfully completed in over 2,000 patients. The TASC trial was a 740 patient, double-blind, placebo controlled trial conceived by Professor Robert West at University College London and funded by the
U.K. National Prevention Research Initiative. The CASCAID trial was a 1,310 patient, single-blind, <FONT STYLE="white-space:nowrap">non-inferiority</FONT> trial comparing cytisine to nicotine replacement therapy (NRT). The CASCAID trial was
conceived by Dr.&nbsp;Natalie Walker, National Institute for Health Innovation, University of Auckland and funded by the Health Research Council of New Zealand. Both trials were published in the New England Journal of Medicine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing of clinical development of cytisine, the
potential market size for cytisine and the potential benefits of cytisine. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product
development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management&#146;s current expectations and
beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisine may not
demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisine; the risk that cytisine will not receive regulatory approval or be successfully
commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve&#146;s intellectual property may not be adequately protected; general
business and economic conditions; and the other factors described in the risk factors set forth in Achieve&#146;s filings with the Securities and Exchange Commission from time to time, including Achieve&#146;s Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances
occurring after the date hereof, other than as may be required by applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Achieve Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason Wong </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jwong@bplifescience.com </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(415) <FONT STYLE="white-space:nowrap">375-3340</FONT> ext. 4 </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">[1]</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">World Health Organization. WHO Report on the Global Tobacco Epidemic, 2011, Geneva: World Health Organization,
2011. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">[2]</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annals of Epidemiology , Volume 25 , Issue 3 , 179 &#150; 182.e1 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g584378g13v56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g584378g13v56.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MSU=>Q_H?_KUZ^%K<\>5[H^5S+"^QJ<\?A?YG35UGEA0 4 % !0 4 % !0 4
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M /%T?5)]T'UB/8/^%V>'?^?#4O\ OW'_ /%T?5)]T'UB/8/^%V>'?^?#4O\
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M: '1R/%(LD;E'0AE93@@CH10,^A?#VJ6_P 1_ [0W#*NH0@)+_LR ?*_T/\
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E+')Y:;Y3(L41)2(''RKG''&>@ZTJ4'!688BJJLDUT6[W?F?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
